Blue Cross Blue Shield RI prostate biomarker Coverage

Coverage and Medical Necessity Criteria

Oncotype DX Prostate — Medically Necessary Criteria

Oncotype DX Prostate (covered for BlueCHiP for Medicare when ALL of the following are met):

Oncotype DX Prostate — Medically necessary when all criteria are met: 1) Prostate needle biopsy specimen demonstrates localized adenocarcinoma of the prostate with no clinical evidence of metastasis or lymph node involvement; 2) Patient has low-risk disease defined as T1–T2a AND Gleason score = 6 AND PSA < 10 ng/mL (D'Amico/NCCN low-risk definitions); 3) Patient has an estimated life expectancy >= 10 years; 4) Patient has not received pelvic radiation or androgen deprivation therapy prior to the biopsy specimen used for testing; 5) Patient is a candidate for and is considering conservative management (active surveillance) but would also be eligible for definitive therapy (radical prostatectomy, radiation therapy, or brachytherapy); 6) Test is ordered by a physician certified in the Genomic Health Oncotype DX Prostate Certification and Training Registry; 7) Patient will be monitored for disease progression according to active surveillance guidelines (e.g., NCCN).all required

Derived from BlueCHiP for Medicare coverage conditions

OncotypeDX AR-V7 Nuclear Detect — Medically Necessary Criteria

OncotypeDX AR-V7 Nuclear Detect (covered for BlueCHiP for Medicare when ALL of the following are met):

OncotypeDX AR-V7 Nuclear Detect — Medically necessary when all criteria are met: 1) Patient has progressive metastatic castration‑resistant prostate cancer (mCRPC) as defined by PCWG2 criteria (eg, rising PSA on serial measurements, new or enlarging bone or soft-tissue lesions); 2) Patient has failed at least one androgen receptor signaling inhibitor (enzalutamide, apalutamide, or abiraterone); 3) Circulating tumor cells (CTCs) will be assessed for nuclear expression of AR‑V7 protein prior to initiation of the next systemic therapy; 4) The treating physician considers the patient appropriate for treatment with an alternative ARSi as a single agent (i.e., results intended to inform whether to use another ARSi versus switch to chemotherapy or other non‑ARSi therapy).all required

Intended to guide sequencing decisions in mCRPC after prior ARSi exposure

AR-V7 testing for sequencing therapy in mCRPC — coverage context and intended use

AR-V7 nuclear test (Oncotype DX AR-V7 Nuclear Detect): coverage context

Intended population: Men with metastatic castration‑resistant prostate cancer (mCRPC) who have failed first‑line ARSi therapy and are considering additional ARSi therapy; testing evaluates nuclear‑localized AR‑V7 protein in circulating tumor cells to inform treatment sequencing.

Clinical rationale: Nuclear AR‑V7 positivity is associated with resistance to ARSi and may identify patients unlikely to benefit from a second ARSi and instead better served by taxane chemotherapy or other non‑ARSi therapies; nuclear localization of AR‑V7 improves clinical specificity for predicting ARSi resistance.

Policy cites evidence and NCCN suggestion that AR‑V7 may help guide therapy

Expected impact: It is expected that approximately 15% of nuclear AR‑V7–positive patients will still receive an ARSi, and nuclear AR‑V7–negative patients receiving ARSi will have similar or better time on therapy compared with untested patients.

ProMark — coverage context (policy position)

ProMark protein biomarker test: coverage context

Intended population: Individuals with low‑ or intermediate‑risk clinically localized untreated prostate cancer; ProMark measures eight tissue proteins and reports a continuous score (0–1) estimating probability of non‑Gleason‑6 pathology.

Evidence summary: Available evidence consists of retrospective clinical‑validity data from archived samples with no clinical‑utility studies; current evidence is insufficient to demonstrate improved health outcomes with ProMark.

Policy concludes evidence does not support improved outcomes

Decipher — coverage context (policy position)

Decipher prostate cancer classifier: coverage context

Intended population: Individuals with localized prostate cancer treated with radical prostatectomy who are being considered for adjuvant or deferred radiotherapy; Decipher reports a continuous genomic risk score (0–1) estimating probability of metastasis.

Evidence summary: Analytic validity and multiple clinical‑validity studies exist, but clinical utility (consistent prediction of who benefits from radiotherapy or improved patient outcomes) is unproven; evidence is insufficient to determine effects on health outcomes.

Policy notes incremental discrimination improvements but unclear utility for therapy selection

For BlueCHiP for Medicare, coverage is limited to the specific assays with defined medical necessity criteria. Use of gene expression analysis and protein biomarkers to manage prostate cancer other than Oncotype DX Prostate and OncotypeDX AR-V7 Nuclear Detect is not covered in all situations because the available evidence is insufficient to determine effects on health outcomes. For Commercial products, use of any gene expression analysis or protein biomarker assay for management of prostate cancer is considered not medically necessary in all situations due to insufficient evidence.

Tests for which only clinical validity evidence from retrospective or single-study cohorts exists, without studies demonstrating clinical utility, are considered to have insufficient evidence to show improved health outcomes. Examples discussed in the evidence review include assays with only archived-sample clinical validity data and no prospective clinical utility studies; the policy therefore considers such tests insufficient to support coverage when intended to change management or improve outcomes.

Specific commercially available tests including Prolaris (CCP score), Decipher (genomic classifier), and ProMark (8-protein tissue biomarker score) are considered investigational or not medically necessary under this policy because current evidence does not demonstrate that use of these assays improves patient health outcomes. For these assays the evidence base is limited to retrospective clinical validity studies or incremental prognostic information without demonstrated clinical utility to guide treatment decisions.

Coding guidance: the policy identifies specific procedure codes that are not covered or not medically necessary for the indicated product lines. Notably, CPT 81541 and the PLA code 0047U are listed as not covered / not medically necessary for the products specified in the policy; unlisted molecular pathology procedures (eg, 81479) require prior authorization.

Coding and Billing Guidance

Coding guidance for genetic testsCPT

Unlisted CPT

No specific CPT coding for some referenced tests; use unlisted CPT code and medical necessity criteria from Genetic Testing Services policy

Not covered / not medically necessary (BlueCHiP for Medicare & Commercial Products)CPTNot Covered

81541

Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes

Not medically necessary / authorization requiredHCPCSNot Covered

0047U

Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 17 genes (Oncotype DX Prostate PLA)

Unlisted tests requiring authorizationCPT

81479

Unlisted molecular pathology procedure

Life expectancy threshold for Oncotype DX Prostate

Life expectancy threshold>= 10 years

ContextRequired for Oncotype DX Prostate medical necessity (patient must have estimated life expectancy >= 10 years)

Source guidanceUsed with risk stratification and consideration of active surveillance vs definitive therapy

Low risk D'Amico criteria (T stage, Gleason score, PSA) used in Oncotype DX Prostate eligibility

D'Amico low-risk T stageT1–T2a

Gleason score

Provider Requirements, Authorization, and Operational Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for the Oncotype DX Prostate Cancer assay and the OncotypeDX AR-V7 Nuclear Detect assay for BlueCHiP for Medicare; prior authorization is required and obtained via the online tool for participating providers. For Commercial products, prior authorization is recommended. For tests filed with an Unlisted CPT code (e.g., 81479), the Genetic Testing Services policy medical necessity criteria and authorization process will be used to determine coverage.

Oncotype DX Prostate Cancer (0047U) — prior authorization required for BlueCHiP for Medicare; see online prior auth tool
OncotypeDX AR-V7 Nuclear Detect — prior authorization required for BlueCHiP for Medicare; see online prior auth tool
Unlisted molecular pathology procedure (81479) and other unlisted/PLA codes — prior authorization required/used for coding review under Genetic Testing Services policy

Documentation Required

Clinical Documentation Required

Submit complete clinical documentation with authorization requests and claims to support medical necessity for covered assays. Documentation should include staging, PSA values, Gleason score, estimated life expectancy, prior treatments, and relevant imaging or progression criteria where applicable.

Clinical Background and Scope

Prostate cancer is frequently clinically localized at diagnosis and is risk-stratified using PSA, clinical T stage, and Gleason score to guide management decisions such as active surveillance versus definitive local therapy. Androgen deprivation therapy is standard for advanced disease, and progression despite castrate levels of testosterone defines metastatic castration-resistant prostate cancer (mCRPC), a setting with multiple life-extending systemic options. Biomarkers have been developed to improve risk stratification and to help sequence systemic therapies: for example, tissue-based gene expression assays may inform decisions about surveillance versus definitive treatment in localized disease, while circulating tumor cell assays for nuclear-localized AR-V7 protein are intended to identify patients with mCRPC who are unlikely to benefit from additional androgen receptor signaling inhibitors and who may be better served by non-ARSi options such as taxane chemotherapy.

Definitions and Test Descriptions

Definition — mCRPC (metastatic castration-resistant prostate cancer)

DefinitionMetastatic castration‑resistant prostate cancer (mCRPC) — disease that progresses while the patient is on androgen deprivation therapy

Clinical contextAfter progression on ADT, continued ADT is generally used with other treatments (eg, ARSi, taxane chemotherapy)

RelevancemCRPC is the intended population for AR‑V7 testing to guide sequencing decisions

Definition — Prolaris CCP score (31 CCP genes + housekeeping genes)

Assay basisProlaris CCP score derived from expression of 31 CCP (cell cycle progression) genes plus 15 housekeeping genes

Intended useProvides prognostic information for localized prostate cancer (low/intermediate risk) and post‑prostatectomy settings

Intended Line of Therapy Use

second-line — criteria node describing intended second-line context

Second‑line context — AR‑V7 intended use: Used in mCRPC after failure of at least one ARSi to guide subsequent choice between another ARSi versus taxane chemotherapy or other non‑ARSi options.

second-line — additional node describing second-line sequencing context

Second‑line sequencing context: Patients who have failed first‑line ARSi and are considering additional ARSi therapy; AR‑V7 nuclear detect is positioned to inform whether to give a second ARSi versus proceed to chemotherapy (taxane) or other non‑ARSi therapy.

Assay and Biomarker Technical Requirements

AR-V7 — nuclear-localized AR-V7 protein expression in circulating tumor cells (biomarker requirement)

Biomarker requirementNuclear-localized AR‑V7 protein expression in circulating tumor cells (CTCs)

Intended useAssessed in men with progressive mCRPC who have failed first‑line ARSi and are considering further ARSi vs alternative therapy

Specimen typeCirculating tumor cells (blood-based test)

AR-V7 (nuclear-localized) — explicit note that nuclear localization defines positive result

Positive result definitionNuclear localization of AR‑V7 protein defines a positive result

RationaleOnly nuclear AR‑V7 protein expression improves clinical specificity for predicting resistance to ARSi

OpenPayer

Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management